PV Bulletin

XEVPRM User Guidance Version 3.21 Update

The EMA has published an updated version of the XEVPRM user guidance, effective 1 January 2026.

Primary source: EMA - What's new RSS

PV Impact Brief

Urgency: HighConfidence: high

What changed

The XEVPRM user guidance has been updated to Version 3.21, which includes detailed instructions for the electronic submission of medicinal product information.

Why it matters

This update specifies operational compliance requirements that marketing authorisation holders must follow to ensure adherence to the regulatory framework, enhancing the efficiency of medicinal product information submissions.

Action needed

Review the updated guidance to incorporate the new compliance procedures starting from 1 January 2026, specifically regarding the electronic submission process.

Relevant for
Regulatory Intelligence LeadPV Quality Lead
Processes impacted
ICSRCountry Compliance
Owner

Regulatory Intelligence Lead

Review cadence

As needed after each guidance update.

Evidence and confidence

Confidence: highSource updated: Sep 9, 2026

Full briefing

Practical implication

Review the updated guidance to incorporate the new compliance procedures starting from 1 January 2026, specifically regarding the electronic submission process.

Chapter 3.II of the XEVPRM detailed user guidance for electronic submission of information on medicinal products by marketing authorisation holders to the EMA is now at Version 3.21, published on 9 September 2026.

What changed: The XEVPRM user guidance has been updated to Version 3.21, which includes detailed instructions for the electronic submission of medicinal product information.

Why it matters: This update specifies operational compliance requirements that marketing authorisation holders must follow to ensure adherence to the regulatory framework, enhancing the efficiency of medicinal product information submissions.

Practical implication: Review the updated guidance to incorporate the new compliance procedures starting from 1 January 2026, specifically regarding the electronic submission process.

View original source

  • Source: EMA - What's new RSS
  • Published at source: 2026-09-09T00:00:00.000Z
  • Discovered by monitor: 2026-09-09T21:44:28.166Z

Published from the regulator source ingestion pipeline after PV impact triage.

#Guidance#Source-ingestion#Regulator-monitor#European Union#Ema.europa.eu#Regulatory Compliance

Related updates for your role

publicEuropean Medicines Agency · European Union · Updated Sep 9, 2026

Electronic submission of Article 57(2) data: questions and answers

Urgency: High

Marketing authorization holders must implement processes to ensure timely submissions of required data within the defined 15 and 30 calendar day timelines, including details of the Qualified Person responsible for Pharmacovigilance and the submission of Pharmacovigilance System Master File information.

ICSRRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, PV Quality Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicEuropean Medicines Agency · European Union · Updated Sep 8, 2026

Human medicines European public assessment report (EPAR): Gardasil 9

Urgency: High

Update labeling materials for Gardasil 9 to incorporate new safety and efficacy data as per the revised EPAR.

LabelingLabeling Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Labeling Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicEuropean Medicines Agency (EMA) · European Union · Updated Sep 8, 2026

Rezolsta (darunavir/cobicistat) European Medicines Agency EPAR Update

Urgency: High

The pharmacovigilance department must increase reporting obligations for any adverse effects related to Rezolsta as part of ongoing safety monitoring.

LabelingSignal ManagementLabeling Lead
SOP Impact2 SOPs
ConfidenceHigh
Relevant for: Labeling Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicEuropean Medicines Agency · European Union · Updated Sep 8, 2026

Kavigale Authorized for COVID-19 Prevention in Immunocompromised Patients

Urgency: High

Healthcare professionals must administer Kavigale in a monitored clinical environment to manage potential severe allergic reactions, including anaphylaxis.

LabelingLabeling Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Labeling Lead
verifiedRegulatory action: Latest
Read impact briefarrow_forward